Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 21, 2019 16:29 ET | Source: Translate Bio, Inc.

Translate Bio Announces Fourth Quarter and Full Year 2018 Financial Results and Reviews Recent Highlights

LEXINGTON, Mass., March 21, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
March 18, 2019 07:30 ET | Source: Translate Bio, Inc.

Translate Bio Announces Publication of Preclinical Data Demonstrating Efficacy of Systemic mRNA Delivery in Fabry Disease Model in the Journal Molecular Therapy

LEXINGTON, Mass., March 18, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
March 04, 2019 07:30 ET | Source: Translate Bio, Inc.

Translate Bio to Present at the 39th Annual Cowen and Company Healthcare Conference

LEXINGTON, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
February 27, 2019 16:30 ET | Source: Translate Bio, Inc.

Translate Bio Provides Updates on Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency Programs

-- Initiated multiple-ascending dose portion of the Phase 1/2 clinical trial of MRT5005 in patients with cystic fibrosis -- -- Received FDA communication related to previously announced IND clinical...
February 14, 2019 07:30 ET | Source: Translate Bio, Inc.

Translate Bio to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference

LEXINGTON, Mass., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
January 22, 2019 07:30 ET | Source: Translate Bio, Inc.

Translate Bio Announces FDA Clinical Hold on Investigational New Drug Application (IND) for MRT5201 for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency

LEXINGTON, Mass., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
January 03, 2019 07:30 ET | Source: Translate Bio, Inc.

Translate Bio Advances Programs in Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency

-- Received approval to begin multiple-ascending dose in Phase 1/2 clinical trial of MRT5005, an mRNA therapeutic for CF -- -- Submitted IND for Phase 1/2 clinical trial of MRT5201, an mRNA...
January 03, 2019 07:30 ET | Source: Translate Bio, Inc.

Translate Bio Appoints Robert Meyer, MD, to its Board of Directors

LEXINGTON, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
December 04, 2018 09:15 ET | Source: Translate Bio, Inc.

Translate Bio Expands Patent Portfolio with Newly Issued U.S. Patent Relating to Its Messenger RNA (mRNA) Therapeutics Platform (MRT™)

LEXINGTON, Mass., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
November 08, 2018 16:21 ET | Source: Translate Bio, Inc.

Translate Bio Announces Third Quarter 2018 Financial Results and Reviews Recent Highlights

Continued progress with ongoing Phase 1/2 clinical trial in CF and towards IND submission for OTC Deficiency LEXINGTON, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right